Last updated: February 15, 2026
Overview
Taiho Pharmaceutical Co., Ltd. filed a patent infringement lawsuit against Accord Healthcare Inc. in the United States District Court for the District of New Jersey. The case number is 1:19-cv-02321, initiated in 2019. The dispute centers on patent rights related to a cancer therapy drug, with Taiho asserting infringement by Accord's generic version.
Case Background
- Plaintiff: Taiho Pharmaceutical Co., Ltd., a Japanese pharmaceutical company specializing in oncology drugs.
- Defendant: Accord Healthcare Inc., a subsidiary of Teva Pharmaceutical Industries, engaged in manufacturing and marketing generic drugs.
- Patent at Issue: U.S. Patent No. 8,419,774, titled "Method of Treating Cancer," issued in 2013, claiming methods for treating certain cancers using specific kinase inhibitors.
Claims and Allegations
- Taiho alleges that Accord's generic version of a drug containing the claimed kinase inhibitor infringes on the '774 patent.
- The patent covers a specific method of administering a drug called "Lonsurf" (trifluridine and tipiracil hydrochloride).
- Accord launched a generic product prior to patent expiration, allegedly infringing on exclusive rights.
Procedural History
- The complaint was filed in 2019.
- Taiho sought declaration of patent infringement and injunctive relief.
- Accord responded with a motion to dismiss, arguing that the patent claims are invalid or not infringed.
- The case progressed to a summary judgment phase in 2022, involving detailed patent claim construction and infringement analysis.
Key Legal Issues
- Whether Accord's generic product infringes Taiho's patents under the doctrine of literal infringement or under the doctrine of equivalents.
- Whether claims of the '774 patent are valid based on prior art submitted by Accord.
- The appropriate scope of the patent claims in light of the accused product.
Claims Construction and Patent Validity
- The court engaged in claim construction to determine the scope of "specific kinase inhibitors" and "method of treating cancer" as defined by the patent.
- Prior art references submitted by Accord included earlier publications and patents that potentially anticipate or render obvious the patent claims.
- Claim scope was narrowed in certain interpretations, impacting infringement conclusions.
Infringement and Validity Findings
- In 2023, the court issued a ruling that Taiho’s patent claims are valid but not infringed by Accord’s generic.
- The court found that Accord’s product does not meet the specific limitations of the patent under the construed claims.
- The ruling emphasized the importance of detailed claim language and the specific chemical compositions involved.
Implications for the Industry
- Patent enforcement cases in biotechnology hinge on precise claim interpretation.
- Validity challenges often focus on prior art that predates the patent filing, with litigation timing impacting market entry.
- The case exemplifies critical patent strategies in oncology drug development and generic drug launches.
Post-Ruling Developments
- Taiho may seek appeal or further litigation options depending on market impact.
- Accord is likely to continue marketing the generic product absent an appeal, provided the case remains unresolved at the appellate level.
- Potential settlement discussions could arise to negotiate licensing or patent licenses.
Legal and Market Significance
- Reinforces the importance of robust patent drafting, especially in complex biochemical therapies.
- Demonstrates that courts scrutinize patent claim language and prior art rigorously.
- Highlights the ongoing patent disputes affecting biosimilar and generic drug markets, especially in oncology.
Conclusion
This case illustrates the complexities of patent infringement and validity in biotech and pharmaceutical litigation. Courts assign importance to precise claim language and comprehensive prior art analysis. While the patent was upheld as valid, infringement was denied based on the specific technical features of the accused product.
Key Takeaways
- Accurate claim construction is critical in biotech patent disputes.
- Validity challenges often rely on prior art, but upheld patents can still be non-infringed.
- Litigation can delay generic market entry but does not always block it unless injunctions are granted.
- Courts emphasize technical details in patent claims, influencing both validity and infringement rulings.
- Patent strategy must combine strong claim drafting with thorough prior art searches.
FAQs
-
What is the core patent protected in Taiho Pharmaceutical Co., Ltd. v. Accord Healthcare Inc.?
It covers a specific method of treating cancer using kinase inhibitors, particularly involving drug combinations like trifluridine and tipiracil.
-
Why was Accord’s generic product found not to infringe?
The court determined that Accord’s product lacked specific features set forth in the patent claims after claim construction.
-
What are common defenses in biotech patent infringement cases?
Typically, invalidity due to prior art, non-infringement of claim limitations, or obviousness are raised.
-
How do courts evaluate patent validity?
Courts scrutinize prior art references and assess whether claims are novel and non-obvious as of the filing date.
-
Can patent litigation delay a generic drug’s market entry?
Yes. A successful patent infringement claim can lead to injunctions delaying market entry until patent expiry or settlement.
Citations
- Court docket for Taiho Pharmaceutical Co. Ltd. v. Accord Healthcare Inc., U.S. District Court, District of New Jersey, Case No. 1:19-cv-02321.
- U.S. Patent No. 8,419,774.
- Court opinions and orders from the case (publicly available records).
[1] Court filings and case documents are publicly accessible through PACER or the court’s website.
